Tag: hereditary transthyretin amyloidosis

Latest articles

Sanofi and GSK COVID-19 vaccine candidate demonstrates positive Phase II results

Sanofi and GSK COVID-19 vaccine candidate demonstrates positive Phase II results

The Sanofi and GlaxoSmithKline (GSK) COVID-19 vaccine candidate has achieved positive results in all adult age groups in a Phase II study with 722...
First Alzheimer’s disease drug candidate designed by AI enters Phase I clinical trials

First Alzheimer’s disease drug candidate designed by AI enters Phase I clinical trials

The world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) is entering Phase I clinical trials, thanks to a successful collaboration...
Colin Prentice, Commercial Director at Evolve

Expand and evolve – when specialist services meet

Specialist recruitment and outsourcing consultancy, Evolve, is pleased to announce the integration of Prentice Associates Ltd. The two specialist organisations have both provided recruitment...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
First Alzheimer’s disease drug candidate designed by AI enters Phase I clinical trials

First Alzheimer’s disease drug candidate designed by AI enters Phase I clinical trials

The world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) is entering Phase I clinical trials, thanks to a successful collaboration...
Challenges in recruiting during the pandemic

Challenges in recruiting during the pandemic

Richard Clegg, Director of Expion Search and Selection, looks at how COVID-19 has presented many challenges to industry, not least in recruitment and retention...
Sanofi and GSK COVID-19 vaccine candidate demonstrates positive Phase II results

Sanofi and GSK COVID-19 vaccine candidate demonstrates positive Phase II results

The Sanofi and GlaxoSmithKline (GSK) COVID-19 vaccine candidate has achieved positive results in all adult age groups in a Phase II study with 722...
Image of a scientist at their lab to show Study shows existing anti-parasitic drug kills coronavirus within 48 hours

Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription